Submitted by Jeffrey Lake on Tue, 11/15/2016 - 12:15pm Please identify your specialty * Dermatologist Allergist Dermatology nurse practitioners Other... Please identify your specialty Other... In which country do you practice medicine? * How confident are you in * Very confidentConfident Reasonably confident, I would like to learn moreNot very confident, I should learn more The diagnosis of atopic dermatitis in your clinical practice? The diagnosis of atopic dermatitis in your clinical practice? - Very confident The diagnosis of atopic dermatitis in your clinical practice? - Confident The diagnosis of atopic dermatitis in your clinical practice? - Reasonably confident, I would like to learn more The diagnosis of atopic dermatitis in your clinical practice? - Not very confident, I should learn more Identifying the level of severity of atopic dermatitis? Identifying the level of severity of atopic dermatitis? - Very confident Identifying the level of severity of atopic dermatitis? - Confident Identifying the level of severity of atopic dermatitis? - Reasonably confident, I would like to learn more Identifying the level of severity of atopic dermatitis? - Not very confident, I should learn more How good is your understanding of the current treatment options for moderate-to- severe atopic dermatitis? * Very good Could be better, I would like to learn more Not good, I should learn more How familiar are you with the mode of action of newly emerging treatment options for moderate-to- severe atopic dermatitis? * Very familiar, I have a complete understanding of the mode of action Familiar, I have a basic understanding of the mode of action I have heard of the mode of action, but cannot recall it Not familiar How familiar are you with the key endpoints used in clinical trials investigating newly emerging treatment options for moderate-to- severe atopic dermatitis, such as the Eczema Area and Severity Index (EASI), Investigator’s Global Assessment (IGA), or Scoring Atopic Dermatitis (SCORAD)? * Very familiar with each of these endpoints Familiar, I have a basic understanding of the endpoints I have heard of at least one of these endpoints Not familiar How aware are you of the clinical profile of newly emerging treatment options for moderate-to- severe atopic dermatitis? * Very aware, I have a complete understanding of newly emerging treatment options Aware, I have a basic understanding of newly emerging treatment options I have heard of newly emerging treatment options, but cannot recall them Not aware Are you familiar with how emerging treatment options could potentially fit in the treatment paradigm of moderate-to- severe atopic dermatitis? * Very familiar, I have complete knowledge Familiar, I have basic knowledge I have heard it before, but cannot recall the information at the moment Not familiar Dupilumab is a monoclonal antibody directed against interleukin (IL)-4 receptor alpha, under development for the treatment of moderate-to- severe atopic dermatitis. How informed are you about the mode of action of this drug? * Well informed Moderately informed Minimally informed Not informed How informed are you about the efficacy and safety of dupilumab in the treatment of moderate-to- severe atopic dermatitis? * Well informed Moderately informed Minimally informed Not informed Are you familiar with the management of the side-effects that may occur if this drug is used? * Very familiar, I have complete knowledge Familiar, I have basic knowledge I have heard about managing the side-effects, but cannot recall the information at the moment Not familiar If you are interested in participating in the raffle for a $100/€100 Amazon gift card, please fill out the following: First Name: Last Name: Email: Leave this field blank
